Nkarta (NKTX) Operating Income (2019 - 2026)
Nkarta's quarterly Operating Income came in at -$30.9 million in Q1 2026, up 15.56% year-on-year from -$26.7 million in Q1 2025, and little changed quarter-over-quarter from -$31.0 million in Q4 2025.
Nkarta has reported Operating Income for 8 years, with the latest figure at -$30.9 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 15.56% year-over-year to -$30.9 million; the trailing twelve-month figure through Mar 2026 stood at -$116.3 million (up 11.88% YoY), and the FY2025 full-year result was -$122.0 million, up 4.83% from the prior year.
- Operating Income for Q1 2026 stood at -$30.9 million, roughly flat from -$31.0 million in the prior quarter.
- The five-year high for Operating Income was -$26.1 million in Q1 2022, with the low at -$36.9 million in Q2 2023.
- Average Operating Income over 5 years is -$31.3 million, with a median of -$30.9 million recorded in 2024.
- Year-over-year, Operating Income sank 52.85% in 2022 and increased 19.26% in 2025.
- Tracing NKTX's Operating Income over 5 years: stood at -$35.0 million in 2022, then grew by 10.86% to -$31.2 million in 2023, then advanced by 0.84% to -$30.9 million in 2024, then fell by 0.12% to -$31.0 million in 2025, then grew by 0.27% to -$30.9 million in 2026.
- The last three Operating Income figures came in at -$30.9 million (Q1 2026), -$31.0 million (Q4 2025), and -$27.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -30.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.88 Mn |
| Dec 31, 2025 | -30.96 Mn |
| Sep 30, 2025 | -27.29 Mn |
| Jun 30, 2025 | -27.19 Mn |
| Mar 31, 2025 | -36.56 Mn |
| Dec 31, 2024 | -30.92 Mn |
| Sep 30, 2024 | -33.79 Mn |
| Jun 30, 2024 | -30.72 Mn |
| Mar 31, 2024 | -32.76 Mn |
| Dec 31, 2023 | -31.19 Mn |
| Sep 30, 2023 | -29.29 Mn |
| Jun 30, 2023 | -36.86 Mn |
| Mar 31, 2023 | -34.31 Mn |
| Dec 31, 2022 | -34.98 Mn |
| Sep 30, 2022 | -30.26 Mn |
| Jun 30, 2022 | -27.61 Mn |
| Mar 31, 2022 | -26.10 Mn |
| Dec 31, 2021 | -22.89 Mn |
| Sep 30, 2021 | -22.43 Mn |
| Jun 30, 2021 | -21.63 Mn |
| Mar 31, 2021 | -19.48 Mn |
| Dec 31, 2020 | -18.00 Mn |
| Sep 30, 2020 | -13.75 Mn |
| Jun 30, 2020 | -10.36 Mn |
| Mar 31, 2020 | -9.41 Mn |
| Dec 31, 2019 | -8.65 Mn |
| Sep 30, 2019 | -5.91 Mn |
| Jun 30, 2019 | -4.67 Mn |